The 1st KSEA STEP-UP on September 21~24, 2020

We hope you are safe and doing well during this highly challenging time. We are very pleased to announce the new KSEA event named “Science and Technology Entrepreneurship Partners’ Upscale Program (STEP-UP)” that is aimed to promote and enrich the KSEA members’ entrepreneurship & partnership and to discuss the success of innovative ventures, especially in the fields of biotech and healthcare.

The STEP-UP event was originally planned for May 8~10, 2020 in Baltimore, Maryland, but was postponed twice due to the COVID-19 pandemic. Now, the STEP-UP comes to us in the online/offline hybrid format for four days on September 21~24, 2020. Seats for the in-person participation are limited and mainly for those who live on a driving distance to Baltimore, MD and the majority of the audience are expected to attend the event virtually. Taking the advantage of the online event, we hope you all can make the STEP-UP to learn and discuss exiting subjects for your future.

The important information below is in the US Eastern time (EDT).

STEP-UP Important Dates

 – Early registration due: September 6, 2020 (Sunday)

 – Registration closure: September 19, 2020 (Saturday)

STEP-UP Program Overview

September 21, 2020 (Monday)

 – Opening and Keynote Speech (20:00 – 20:55)

 – Academic Entrepreneurship (21:00 – 23:00 – A)

 – Entering the US Market (21:00 – 23:00 – B)

September 22, 2020 (Tuesday)

 – FDA and Regulatory Strategy (20:00 – 23:30)

September 23, 2020 (Wednesday)

 – IP Strategy and the Law (20:00 – 23:00)

September 24, 2020 (Thursday)

 – Fundraising (20:00 – 22:20)

 – Closing (22:30 – 23:00)

You can find more details and register for the event at the STEP-UP website, stepup.ksea.org.

Please register early to receive the special discount of $100 for early registrants. You will also receive an additional discount of $100 if you are a current term member of KSEA.

We look forward to seeing you soon at the event.

Cheers,

Kyeong Ho Yang, Ph.D., STEP-UP Chair
Soolyeon Cho, Ph.D., KSEA President

Korean-American Scientists and Engineers Association (KSEA) 
Website: https://ksea.org/
Facebook: https://www.facebook.com/KSEA.HQ/

2nd KAPAL On-Air Webinar – Maryland’s Biotech Cluster (Sep 16, 2020, 9:00 – 11:00 PM EST)

Maryland’s Biotechnology Cluster 온라인 설명회는 한미생명과학인 협회 (KAPAL)와 KHIDI 미국지사 웨비나 시리즈입니다.

About this Event

안녕하세요. 코로나로 일상생활에 지장이 많은 요즘, 모든 가정과, 하시는 모든 일이 평안하시길 저희 한미 생명과학인 협회(KAPAL)는 진심으로 바랍니다.

다음이 아니라, “KAPAL 2nd On-Air Webinar” 가 돌아오는 9월 16일 , 미동부 시간으로 저녁 9시(한국시간 9월 17일 오전 10:00 시)에 개최됩니다.

이번 웨비나는 “한국 바이오 기업들이 메릴랜드에 진출하기 위한 전략과 이점” 을 주제로 진행되며, 메릴랜드에 이미 정착해 성장하고 있는 기업들도 초청하여 다양한 사례를 듣는 시간도 준비하였습니다.

특히, 메릴랜드 주정부에서는 바이오 및 생명과학 기업에게 전폭적으로 지원하는 다양한 프로그램에 관해 발표합니다. 아울러 현재 코비드19 진단및 관련기업에 대해 메릴랜드에 상황에 대해서도 발표준비를 하고 있습니다.

제 2회 카팔 웨비나는 한국 보건산업 진흥원 미국지사 (KHIDI-USA)와 협력하여 공동주최며, 메릴랜드 주정부에서 동참합니다.

또한 미리 궁금하신 사항이나 질문들을 contact@kapal.org 로 보내주시면, 저희가 의견들을 수렴하여 더욱 알찬 웨비나를 만드는데 도움이 될 것입니다. 그 뿐 아니라 질응답에도 반영하여 준비하니, 많은 의견과 궁금하신 사항들은 위의 주소로 이메일 보내주시기 바랍니다.

Maryland is the heart of the BioHealth Capital Region – one of the leading American biotech / life sciences clusters with more employed doctoral scientists per capita than any other U.S. state. But what does that actually mean?

Dr. Ernesto Chanona will break down our bio cluster to explain why Maryland is relevant for your business, introducing key national, state, and private institutions. He will highlight therapeutic areas, such as infectious diseases, oncology, neurology, surgical procedures and wound care, and provide an overview of current COVID-19 activity. Dr. Chanona will also discuss funding programs and venture capital. Ms. Felicia Pullam will explain the services that the Maryland Department of Commerce can provide to Korean companies at no charge.

2nd KAPAL On-Air Webnar Program

Webinar Access: To be noticed by email

프로그램 (9/16 저녁 9시 미동부시간, 9/17 오전 10:00 한국시간)

9:00 – 9:10 PM (미동부) 10:00 – 10:10 AM (한국)

Opening remarks by First lady Yumi Hogan (Maryland)

Matthew Oh (KHIDI-USA)

Luke Oh (KAPAL)

9:10  – 9:30 PM (미동부) 10:10 – 10:30 AM (한국)

Korean-American Bioscience Industry Ecosystem in Maryland

한국기업의 정착 및 발전사례

– NeoImmuneTech

NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and complemented by a strong executive team with rich industry experience at companies such as Novartis, BMS, GSK, Pfizer, Amgen, Eli Lilly, MedImmune/AstraZeneca and PwC. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics.

Dr. Byung Ha Lee is the R&D Director at NeoImmuneTech, Inc. With Ph.D. degrees from the University of Florida College of Medicine. He has extensive industry experience over 15 years in translational research, business development, field KOL interaction, leading strategic and research planning of drug development. He finished his postdoctoral training at the NIAID at NIH. Before joining NIT, he was the principal investigator of first-in-class pipelines and Senior Manager of Strategy planning in Genexine Inc. (a public biotech company in Korea). He is known for his strong scientific knowledge in immuno-oncology and immune cell biology in diseases.

– KCRN Research

– TeraImmune

테라이뮨(Teraimmune,Inc.)은 조절 T세포를 이용한 세포치료제를 개발하는 회사입니다. 내성항체, 다발성경화증, 이종장기이식 그리고 아토피성 피부염에 대한 세포치료제를 개발 중이며, 표적특이적 수용체(TCR, CAR)와 결합하여 질병 특이적인 치료제를 개발하는 것이 목표입니다. 2021년 혈우병 치료제 FVIII에 대한 내성항체 생성을 극복할 수 있는 TCR-Treg으로 미국에서의 임상시험을 준비하고 있습니다. 현재 미연방정부 공동연구프로그램인 CRADA를 통해 미국립보건원 및 미국방부 군의관 양성대학과 함께 연구를 진행하고 있습니다.

박지훈 박사 (Jay Park, Ph.D) 는 테라이뮨의 공동창업자이자 운영책임(COO)을 맡고 있습니다. 한국에서 생화학 박사학위를 받고 2014년부터 미국립보건원의 NHLBI에서 박사 후 연수를 하였으며, 2018년 11월 정식으로 테라이뮨에 참여하여 지금까지 회사를 운영해오고 있습니다.

9:30 – 10:30 PM (미동부) 10:30 – 11:30 AM (한국)

Ernesto Chanona, Ph.D.

Manager, Business and Innovation Development

Office of BioHealth & Life Sciences, Maryland Department of Commerce

Felicia Pullam

Regional Manager, Asia

Office of International Investment and Trade, Maryland Department of Commerce

10:30 – 11:00 PM (미동부) 11:30 AM – 12:00 PM (한국)

Q&A

*******************************************

KAPAL On-Air Webinar registration link (Free registration)

[Teraimmune] Scientist I, R&D

테라이뮨에서 Engineered T cell을 이용하여 B-cell lymphoma 치료제 개발 연구를 함께 하실 프레시 박사 (2년 경력 이내) 분을 모집하고 있습니다.

Job Description
Title: Scientist I
Division: Research and Development
Type of employment: full-time, annual employment renewal
Available number of positions: 1
Deadline for applications: 9/11/2020


The successful candidate will put his or her research efforts in the discovery and development of immune cell derived therapeutics for the treatment of B-cell lymphomas. S/he will participate as a team member driving research programs forward the development and discovery of proof of concept studies of new pipelines of the business as well as research programs across different stages of pre-clinical live cell therapeutics. The successful candidate must be motivated to design, execute, and interpret studies for the development of a new therapeutics, and also validation and characterization of engineered immune cell therapeutic products but not limited. The fellow is encouraged to effectively and frequently collaborate with multidisciplinary teams.


About the Company:
TeraImmune, Inc. is a Maryland-based startup company developing immune therapeutics using regulatory T cells (Tregs). By combining target specific receptors with Tregs, the company provides CAR-Treg and TCR-Treg technologies to help the patients with autoimmune diseases. In addition to Treg immunology, TeraImmune is expanding its range of scope in immune therapies to other immune cells and biologics as well as cancer therapeutics. TeraImmune is now looking for enthusiastic and motivated scientists to prepare the first-in-human clinical trials with the gene engineered Tregs followed by anti-cancer therapy.


Primary responsibilities (include, but are not limited to):
The successful candidate must lead a project as a scientist to develop an anti-cancer cell therapy. Expertise to design, perform and interpret data in vitro and ex vivo experiments with experience in immunology, cancer biology or cell biology is required. Proficiency in cell biology assays that may include flow cytometry, ELISA, cell proliferation, cellular cytotoxicity, immune cell isolation from whole blood or tissues, cell culture, transfection and cloning to generate stable cell lines is expected but not necessary. Previous experience with T cell biology with characterization of immune cell subsets is highly desirable. Analyzing and presenting data in peer-reviewed journals or conferences is required. Working independently to manage time and multiple experiments simultaneously is necessary for this position.
Successful candidate may have to contribute to various projects outside of his/her own and collaborate with stakeholders from all relevant functions and must demonstrate clear and professional verbal and written communication skills.

Basic Requirements
The candidate should hold an MD, PhD or DVM degree with less than 2 years of experience or acquiring the degree before hiring with wet lab experience. The successful candidate is expected to have experiences in performing progressive and advanced duties, or the equivalent training/experience. Strong knowledge on cell biology or immunology with understanding and performing flow cytometry is a big plus. Previous experience in tissue culture is highly expected.

Benefits
The company fully supports health and dental insurance as a group. If required, the company is willing to petition VISA or green card application, but the applicant is responsible for the processing and legal fee.


If you are interested in TeraImmune, please email a cover letter containing your interest experiences with a separate CV or resume as well as the contact information of at least two referees to HR manager at recruiting@teraimmune.com. Please feel free to email the HR manage with any questions.
For more information, please see website: www.teraimmune.com

Online Training Courses for Drug Development from KIOSC Training Center (From Aug 31, 2020)

KIOSC Training Center is opening the 2nd season of online training courses for drug development as follows:
• US Regulatory Affairs – Part 1 (Greg Hockel, PhD): Tuesday 8pm, EST (6 sessions from Sep 1 to Oct 14, 2020)
• US Site Management (Dan Sfera): Thursday 8pm, EST (8 sessions from Sep 3 to Oct 29, 2020)
• Biostatistics for Non-statistician (Noha Lim, PhD): Monday 8pm, EST (4 sessions from Aug 31 to Sep 21, 2020) – Training course in Korean

Each session costs $75 for a 60-minute online lecture, and session slides and certificates will be provided to attendees (no recording files provided).
KAPAL members will receive a 20% discount that can be used for all sessions planned this year.
KAPAL members, please register training sessions using the following discount code: 2020KAPAL20OFF.

Please visit the following website where you can view information about the proposed training courses and instructors and register a training session: https://training.kiosc.org/

If you have any questions for these training opportunities, please contact KIOSC Training Center (info@kiosc.org).

[Teraimmune] Research associate

Job Description:
Title: Research associate
Division: R&D
Type of employment: full-time
Available number of positions: 2

The candidate will join the research efforts in the discovery and development of immune cell derived therapeutics for the treatment of autoimmune diseases. S/he will be part of a team driving forward research programs across the different stages of pre-clinical live cell drug discovery. Responsibilities include the design, execution, and interpretation of studies for the validation and characterization of engineered immune cell therapeutic products. The scientist will effectively and frequently collaborate with colleagues in the present scientific results to multidisciplinary teams.

The Company:
TeraImmune, Inc. is a Maryland-based startup developing immune cell therapies using regulatory T cells (Tregs). By combining target specific receptors with Tregs, the company provides CAR-Treg and TCR-Treg technologies to help the patients with autoimmune diseases. TeraImmune is now looking for enthusiastic and skillful researchers to prepare the first-in-human clinical trials with the gene-engineered Tregs.

Primary responsibilities (include, but are not limited to):
Ability to design, perform and interpret data in vitro and ex vivo experiments. Proficient in cell biology assays that could include flow cytometry, ELISAs, cell proliferation, cellular cytotoxicity, immune cell isolation from whole blood or tissues, cell culture, transfection and cloning to generate stable cell lines. Previous experience with cytokine profiling with flow cytometry is desirable. Characterization of immune cell subsets e.g., regulatory T cells. Ability to analyze and present data in professional publication ready format and work independently to manage multiple experiments simultaneously.
Candidate will contribute to various projects outside of his/her own and collaborate with stakeholders from all relevant functions and must demonstrate clear and professional verbal and written communication skills.
Typically, the candidate should have an M.S. with 3-5 years of experience, or a B.S./B.A. with 4-6 years of experience, performing progressively advanced duties, or the equivalent training/experience. Strong cell biology and understanding of flow data skills are required. Previous experience of tissue culture is required. A good background in immunology is desirable. Prior laboratory experience is preferred.

Benefits:
The company fully supports group medical, prescription and dental insurance. If required, the company can sponsor VISA or green card application, but the applicant is responsible for the processing and legal fee.
If you are interested in joining TeraImmune, please email Jay Park at jpark@teraimmune.com.
Website: www.teraimmune.com

* TeraImmune, Inc. is an equal opportunity employer committed to employing a diverse workforce, including, but not limited to, minorities, females, individuals with disabilities, protected veterans, sexual orientation, gender identity Equal Employment Opportunity is The Law